Diagnosis and Treatment of Osteoporosis in CKD
View More View Less
  • 1 Department of Nephrology, Monash Health, Clayton, Victoria, Australia
  • 2 Department of Medicine, Monash University, Clayton, Victoria, Australia
  • 3 Columbia University Irving Medical Center, Department of Medicine, Division of Nephrology, New York, NY
  • 1.

    Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res 9: 11371141, 1994 PubMed

  • 2.

    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785795, 2001 PubMed

    • Search Google Scholar
    • Export Citation
  • 3.

    Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. ; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 19451953, 2006 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s changed and why it matters. Kidney Int 92: 2636, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Damasiewicz MJ, Ebeling PR: Management of mineral and bone disorders in renal transplant recipients. Nephrology (Carlton) 22[Suppl 2]: 6569, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385397, 2008 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Miller PD: Bone disease in CKD: A focus on osteoporosis diagnosis and management. Am J Kidney Dis 64: 290304, 2014 PubMed

  • 8.

    National Kidney Foundation. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-CKD-MBD-Guideline-English.pdf. Accessed XXX XX, xxxx

    • Search Google Scholar
    • Export Citation
  • 9.

    Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. : Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 13581366, 2006 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Miller PD: Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 41: 613628, 2012 PubMed

  • 11.

    Fahal IH: Uraemic sarcopenia: aetiology and implications. Nephrol Dial Transplant 29: 16551665, 2014 PubMed

  • 12.

    West SL, Jamal SA, Lok CE: Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant 27: 23842388, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Klawansky S, Komaroff E, Cavanaugh PF, Mitchell DY, Gordon MJ, Connelly JE, Ross SD: Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int 14: 570576, 2003

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Nickolas TL, McMahon DJ, Shane E: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17: 32233232, 2006 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, et al. : The three-year incidence of fracture in chronic kidney disease. Kidney Int 86: 810818, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Coco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 11151121, 2000 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Isakova T, Craven TE, Scialla JJ, Nickolas TL, Schnall A, Barzilay J, et al. ; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone 78: 2327, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Arneson TJ, Li S, Liu J, Kilpatrick RD, Newsome BB, St Peter WL: Trends in hip fracture rates in US hemodialysis patients, 1993–2010. Am J Kidney Dis 62: 747754, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Nair SS, Mitani AA, Goldstein BA, Chertow GM, Lowenberg DW, Winkelmayer WC: Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol 8: 13361342, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Kim SM, Liu S, Long J, Montez-Rath ME, Leonard MB, Chertow GM: Declining rates of hip fracture in end-stage renal disease: Analysis from the 2003–2011 nationwide inpatient sample. J Bone Miner Res 32: 22972303, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Wagner J, Jhaveri KD, Rosen L, Sunday S, Mathew AT, Fishbane S: Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant 29: 146151, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Beaubrun AC, Kilpatrick RD, Freburger JK, Bradbury BD, Wang L, Brookhart MA: Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients. J Am Soc Nephrol 24: 14611469, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Kim SM, Long J, Montez-Rath M, Leonard M, Chertow GM: Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res 31: 18031809, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Damasiewicz MJ, Nickolas TL: Rethinking bone disease in kidney disease. JBMR Plus 2: 309322, 2018 PubMed

  • 25.

    Mora Palma FJ, Ellis HA, Cook DB, Dewar JH, Ward MK, Wilkinson R, et al. : Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med 52: 332348, 1983 PubMed

    • Search Google Scholar
    • Export Citation
  • 26.

    Carvalho C, Magalhães J, Neto R, Pereira L, Branco P, Adragão T, et al. : Cortical bone analysis in a predialysis population: A comparison with a dialysis population. J Bone Miner Metab 35: 513521, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, et al. : Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 11: 813819, 1996 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. : Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358363, 1995 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Malluche HH, Ritz E, Lange HP, Kutschera L, Hodgson M, Seiffert U, et al. : Bone histology in incipient and advanced renal failure. Kidney Int 9: 355362, 1976 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Malluche HH, Mawad HW, Monier-Faugere MC: Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26: 13681376, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. : Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67: 559566, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, et al. : Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients: A single-center cohort study. Nephrol Dial Transplant 27: 345351, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB, et al. ; Health, Aging, and Body Composition Study: Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7: 11301136, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Naylor KL, Garg AX, Zou G, Langsetmo L, Leslie WD, Fraser LA, et al. : Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 10: 646653, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Jamal SA, West SL, Nickolas TL: The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 25: 7176, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Przedlacki J, Buczyńska-Chyl J, Koźmiński P, Niemczyk E, Wojtaszek E, Gieglis E, et al. ; Mazovia Fracture Study Group: The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: A two-year prospective multicenter cohort study. Osteoporos Int 29: 11051115, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37.

    Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, et al. : Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28: 18111820, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    Trombetti A, Stoermann C, Chevalley T, Van Rietbergen B, Herrmann FR, Martin PY, et al. : Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int 24: 17211732, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Nickolas TL, Cremers S, Zhang A, Thomas V, Stein E, Cohen A, et al. : Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 22: 15601572, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Cejka D, Patsch JM, Weber M, Diarra D, Riegersperger M, Kikic Z, et al. : Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol 6: 22642271, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Jamal S, Cheung AM, West S, Lok C: Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int 23: 28052813, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    Pothuaud L, Carceller P, Hans D: Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: Applications in the study of human trabecular bone microarchitecture. Bone 42: 775787, 2008 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Iki M, Tamaki J, Kadowaki E, Sato Y, Dongmei N, Winzenrieth R, et al. : Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: The Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res 29: 399407, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44.

    Luckman M, Hans D, Cortez N, Nishiyama KK, Agarawal S, Zhang C, et al. : Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients. Clin J Am Soc Nephrol 12: 644652, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, et al. : A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31: 940948, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46.

    Muschitz C, Kocijan R, Haschka J, Pahr D, Kaider A, Pietschmann P, et al. : TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79: 259266, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Naylor KL, Prior J, Garg AX, Berger C, Langsetmo L, Adachi JD, et al. : Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function. Clin J Am Soc Nephrol 11: 20322040, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    Malluche HH, Monier-Faugere M-C, Blomquist G, Davenport DL: Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Osteoporosis Int 65: 235134, 2017

    • Search Google Scholar
    • Export Citation
  • 49.

    Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB: Incidence and mortality of hip fractures in the United States. JAMA 302: 15731579, 2009 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50.

    Khairallah P, Nickolas TL: Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13: 962969, 2018 PubMed

  • 51.

    Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, et al. : KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 70: 737751, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52.

    Titan SM, Laureati P, Sang Y, Chang AR, Evans M, Trevisan M, et al. : Bisphosphonate utilization across the spectrum of eGFR. Arch Osteoporos 15: 6979, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 53.

    Damasiewicz MJ, Nickolas TL: Bisphosphonate therapy in CKD: The current state of affairs. Curr Opin Nephrol Hypertens 29: 221226, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54.

    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res 20: 21052115, 2005 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 55.

    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. : Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res 22: 503508, 2007 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 56.

    Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: Post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol 18: 6673, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 57.

    Sugimoto T, Inoue D, Maehara M, Oikawa I, Shigematsu T, Nishizawa Y: Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: A post hoc subgroup analysis of a phase III trial in Japan. J Bone Miner Metab 37: 730740, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58.

    Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG: Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56: 5768, 2010

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59.

    Ali MS, Ernst M, Robinson DE, Caskey F, Arden NK, Ben-Shlomo Y, et al. : Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: An open cohort multivariable and propensity score analysis from Funen, Denmark. Arch Osteoporos 15: 8192, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 60.

    Alarkawi D, Ali MS, Bliuc D, Pallares N, Tebe C, Elhussein L, et al. : Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (Grade 3B-5D) chronic kidney disease: A population-based cohort study. J Bone Miner Res 35: 894900, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 61.

    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. ; FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756765, 2009 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62.

    Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. : Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26: 18291835, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Dave V, Chiang CY, Booth J, Mount PF: Hypocalcemia post denosumab in patients with chronic kidney disease stage 4–5. Am J Nephrol 41: 129137, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 64.

    Block GA, Bone HG, Fang L, Lee E, Padhi D: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27: 14711479, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 65.

    Chen CL, Chen NC, Hsu CY, Chou KJ, Lee PT, Fang HC, et al. : An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99: 24262432, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66.

    Festuccia F, Jafari MT, Moioli A, Fofi C, Barberi S, Amendola S, et al. : Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 30: 271279, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 67.

    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. : Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 14341441, 2001 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68.

    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. : Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 20282039, 2007 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 69.

    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18: 5968, 2007 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 70.

    Imai H, Watanabe M, Fujita T, Watanabe H, Harada K, Moritoyo T; ANTCliPh (Academic Network for Trials in Clinical Pharmacology ) Trial 04 Study Group: Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: A pilot study. Int J Clin Pharmacol Ther 52: 166174, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 71.

    Cejka D, Kodras K, Bader T, Haas M: Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study. Kidney Blood Press Res 33: 221226, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 72.

    Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T, et al. : Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int 27: 14411450, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 73.

    Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G: Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int 99: 489499, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 74.

    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. ; ACTIVE Study Investigators: Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA 316: 722733, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75.

    Moreira CA, Fitzpatrick LA, Wang Y, Recker RR: Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone 97: 314319, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 76.

    Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. : Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375: 15321543, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 77.

    McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. : Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370: 412420, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78.

    Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. : Romosozumab or alendronate for fracture prevention in women with osteoporosis. n engl j med 377: 14171427, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 79.

    Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. : Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet 390: 15851594, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 1353 1353 374
Full Text Views 389 389 45
PDF Downloads 342 342 55